• +1-646-491-9876
    • +91-20-67278686

    Search

    Lyme Disease - Pipeline Review, H1 2017

    Lyme Disease - Pipeline Review, H1 2017

    • Report Code ID: RW0001689427
    • Category Healthcare
    • No. of Pages 33
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Lyme Disease - Pipeline Review, H1 2017, provides an overview of the Lyme Disease (Infectious Disease) pipeline landscape.

    Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches and headache. Risk factors include age, gender and geographic locations. Treatment includes antibiotics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Lyme Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Lyme Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Lyme Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Lyme Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Lyme Disease (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Lyme Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Lyme Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Lyme Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Lyme Disease (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Lyme Disease (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Lyme Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Lyme Disease - Overview
    Lyme Disease - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Lyme Disease - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Lyme Disease - Companies Involved in Therapeutics Development
    LondonPharma Ltd
    NovoBiotic Pharmaceuticals LLC
    Valneva SE
    Lyme Disease - Drug Profiles
    azithromycin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lyme disease vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lyme disease vaccine 2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Lyme Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Lyme Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VLA-15 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Lyme Disease - Dormant Projects
    Lyme Disease - Product Development Milestones
    Featured News & Press Releases
    Dec 09, 2016: Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate
    Jul 12, 2016: European Investment Bank Grants Valneva a EU25 Million Loan to Fund R&D Activities
    Mar 24, 2016: VALNEVA to present at the 16th World Vaccine Congress in Washington D.C.
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Lyme Disease, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Lyme Disease - Pipeline by LondonPharma Ltd, H1 2017
    Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017
    Lyme Disease - Pipeline by Valneva SE, H1 2017
    Lyme Disease - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Lyme Disease, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    LondonPharma Ltd
    NovoBiotic Pharmaceuticals LLC
    Valneva SE

    Request for Sample

    Report Url http://www.reportsweb.com//lyme-disease-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//lyme-disease-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//lyme-disease-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments